June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Visual Function Measurements from the nGoggle are Associated with Patient-Reported Quality of Life in Glaucoma
Author Affiliations & Notes
  • Carolina Nicolela Susanna
    Faculdade de Medicina do ABC, São Paulo, São Paulo, Brazil
    Ophthalmology, University of California San Diego, San Diego, California, United States
  • Fabio B Daga
    Ophthalmology, University of California San Diego, San Diego, California, United States
  • Masaki Nakanishi
    Ophthalmology, University of California San Diego, San Diego, California, United States
    Neural Computation, University of California San Diego, San Diego, California, United States
  • Bianca Nicolela Susanna
    Faculdade de Medicina do ABC, São Paulo, São Paulo, Brazil
    Ophthalmology, University of California San Diego, San Diego, California, United States
  • Yu-Te Wang
    Neural Computation, University of California San Diego, San Diego, California, United States
  • Remo Susanna
    Ophthalmology, Universidade de São Paulo, São Paulo, Brazil
  • Nara G. Ogata
    Ophthalmology, University of California San Diego, San Diego, California, United States
  • John Zao
    nGoggle Inc., , San Diego, California, United States
  • Tzyy-Ping Jung
    nGoggle Inc., , San Diego, California, United States
    Neural Computation, University of California San Diego, San Diego, California, United States
  • Felipe Medeiros
    Ophthalmology, University of California San Diego, San Diego, California, United States
    nGoggle Inc., , San Diego, California, United States
  • Footnotes
    Commercial Relationships   Carolina Susanna, None; Fabio Daga, None; Masaki Nakanishi, None; Bianca Nicolela Susanna, None; Yu-Te Wang, None; Remo Susanna, Alcon Laboratories Inc (C), Allergan, Inc (C), Mundipharma (C); Nara Ogata, None; John Zao, nGoggle (I); Tzyy-Ping Jung, nGoggle (I); Felipe Medeiros, Alcon Laboratories Inc (R), Alcon Laboratories Inc (F), Allergan Inc (R), Allergan Inc (F), Allergan Inc (C), Bausch & Lomb (F), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec Inc (R), Carl Zeiss Meditec Inc (C), Heidelberg Engineering Inc (F), Merck Inc (F), National Eye Institute (F), nGoggle (I), Novartis (C), Reichert Inc (R), Reichert Inc (F), Sensimed (F), Topcon Inc (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3298. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Carolina Nicolela Susanna, Fabio B Daga, Masaki Nakanishi, Bianca Nicolela Susanna, Yu-Te Wang, Remo Susanna, Nara G. Ogata, John Zao, Tzyy-Ping Jung, Felipe Medeiros; Visual Function Measurements from the nGoggle are Associated with Patient-Reported Quality of Life in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3298.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The nGoggle (nGoggle, Inc., San Diego, CA) is a portable brain-computer interface designed to objectively assess functional loss in glaucoma and other eye diseases. A previous study has shown that nGoggle measurements are associated with visual field loss detected by standard automated perimetry (SAP). This study aimed at investigating whether functional loss measured by the nGoggle is also associated with patient-reported quality of life outcomes, as assessed by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

Methods : 37 glaucoma patients and 14 healthy individuals were included in the study. All subjects were tested by the nGoggle, SAP SITA 24-2 and also responded NEI VFQ-25 questionnaires. The nGoggle is a portable device that integrates wearable, wireless, dry electroencephalogram and electrooculogram systems, and a head-mounted display (HMD), allowing detection of multifocal steady-state visual evoked potentials (mfSSVEP) associated with visual field stimulation (Figure 1). Rasch analysis was performed to obtain final scores of disability as measured by the NEI VFQ-25. Linear regression models were used to investigate the association between NEI VFQ-25 Rasch-calibrated scores and the global nGoggle mfSSVEP parameter, as well as SAP Mean Deviation (MD). Analyses were performed for the better and worse eyes for both nGoggle and SAP.

Results : Patients with glaucoma had significantly worse nGoggle mfSSVEP measurements compared to healthy subjects (0.300 +- 0.233 vs. 0.342 +- 0.022, respectively; P<0.001). There was a statistically significant relationship between nGoggle measurements in the better eye and NEI VFQ-25 scores (r=0.352; P=0.011). Similar results were found for the worse eye. SAP MD in the better eye had a similar correlation to NEI VFQ-25 scores (r=0.347; P=0.013). In a multivariable model adjusting for age, gender, and race, nGoggle mfSSVEP measurements were still significantly associated with NEI VFQ-25 scores (P=0.010).

Conclusions : Assessment of neural damage by the nGoggle was significantly associated with patient-reported quality of life outcomes as measured by the NEI VFQ-25. This finding indicates that nGoggle measurements are indicative of patient disability and may be useful biomarkers for functional loss in glaucoma.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×